INBX - NASDAQ
Inhibrx Biosciences, Inc.
$95.22
+1.7%Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
At a Glance
Live SnapshotInhibrx Biosciences, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Negative gross margin indicates the company is losing money on each sale—unsustainable long-term.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
Inhibrx Biosciences, Inc. Income Statement
INBX • NASDAQ
| Inhibrx Biosciences, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||
1.3M | 200K | 1.8M | 2.2M | 7.1M | 12.8M | 9.1M | 7.5M | 8M | 6.7M | |
GROSS PROFIT | ||||||||||
(2.5M) | (2.3M) | (1.2M) | (110.2M) | (2.7M) | (73.5M) | (47.9M) | (33.5M) | (25.5M) | (17M) | |
-1.2M | -2.1M | 609K | -108M | 4.4M | -60.7M | -38.8M | -26M | -17.6M | -10.3M | |
OPERATING INCOME | ||||||||||
(133.8M) | (329.4M) | (219.8M) | (21.1M) | (12.3M) | (80.3M) | (52.8M) | (37M) | (27.7M) | (18.6M) | |
(23.3M) | (127.9M) | (29.4M) | (21.1M) | (12.4M) | (6.8M) | (9M) | (4.7M) | (2.6M) | (1.6M) | |
(113M) | (203.7M) | (190.6M) | (110.2M) | (71.4M) | (73.5M) | (47.9M) | (33.5M) | (25.5M) | (17M) | |
-135M | -331.4M | -219.2M | -129.1M | -76.6M | -67.4M | -43.7M | -29.5M | -19.7M | -12.1M | |
PRE-TAX INCOME | ||||||||||
(12.2M) | (13.5M) | (31.8M) | (16.1M) | (5.2M) | (10.8M) | (5.7M) | (1.5M) | (2.1M) | (0.0) | |
-4.6M | -2.6M | -19.9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-2.5M | -2.3M | -199K | -110.2M | -71.5M | -80K | -4.1M | (68K) | (24K) | (0.0) | |
-5M | 2B | -20.5M | -16.1M | -5.2M | -8.2M | -6.8M | -1.4M | -2.1M | -739K | |
-140.1M | 1.7B | -239.7M | -145.2M | -81.8M | -75.6M | -50.5M | -30.9M | -21.8M | -12.9M | |
NET INCOME | ||||||||||
(2K) | (2K) | (3K) | (3K) | (2K) | (3K) | (898K) | (96K) | (250K) | -4.6M | |
-140.1M | 1.7B | -241.4M | -145.2M | -81.8M | -75.6M | -51.4M | -31.2M | -19.4M | -8.3M |
SEC Filings
INBX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 03, 2026 | June 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 23, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | April 21, 2026 | April 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 19, 2026 | March 19, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 19, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 23, 2026 | February 23, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 16, 2025 | December 16, 2025 | 2025 |
Related Guides
Continue your INBX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.